← Back to Search

Topical Agent

Padagis active product for Plaque Psoriasis

Phase 3

Waitlist Available

Research Sponsored by Padagis LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 to day 56

Awards & highlights

Study Summary

This trial tested a new treatment for plaque psoriasis compared to an approved one to see which was safer and more effective.

Eligible Conditions

Plaque Psoriasis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 to day 56

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 to day 56

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 56 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Investigator's Global Assessment (IGA)

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: Padagis active productExperimental Treatment1 Intervention

Group II: Reference productActive Control1 Intervention

Group III: Padagis placebo productPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

roflumilast cream 0.3%

2023

Completed Phase 3

~420

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Padagis LLCLead Sponsor

36 Previous Clinical Trials

20,435 Total Patients Enrolled

Media Library

roflumilast cream 0.3% (Topical Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05763082 — Phase 3

Plaque Psoriasis Research Study Groups: Padagis active product, Reference product, Padagis placebo product

Plaque Psoriasis Clinical Trial 2023: roflumilast cream 0.3% Highlights & Side Effects. Trial Name: NCT05763082 — Phase 3

roflumilast cream 0.3% (Topical Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05763082 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the participant quota for this research investigation?

"Affirmative. The details hosted on clinicaltrials.gov indicate that the research has been recruiting since February 7th, 2023 and was last modified on February 28th, 2023. 450 participants need to be sourced from a single location for this investigation to move forward."

Answered by AI

Can participants below the age of sixty join this research project?

"For this clinical trial, patients between the ages of 12 to 75 are eligible for enrollment. Subsequently, there are 32 separate studies focusing on minors and 140 dedicated to seniors."

Answered by AI

Has Padagis's latest invention received Federal Drug Administration clearance?

"Padagis active product has been assigned a risk rating of 3 due to past clinical evidence, which suggests the drug is both efficacious and safe."

Answered by AI

Are there any remaining spots in this experiment open to applicants?

"Affirmative. According to information hosted on clinicaltrials.gov, this medical research project is actively enrolling patients. It was first posted on February 7th 2023 and recently updated at the end of the month; 450 volunteers are necessary from only 1 site."

Answered by AI

Are there particular individuals that are better suited to enroll in this study?

"Candidates hoping to be enrolled in this study must have a diagnosis of plaque psoriasis and are required to fall between the ages of 12 and 75. In total, 450 individuals will be accepted into the trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

2023. "Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05763082.